27 September 2024 Antibody-drug conjugates (ADCs) represent a significant advancement in cancer treatment, particularly within China's burgeoning oncology sector.
Shares of German pharma major Bayer were up 4.6% at 30.45 euros after it released positive early trial results for its Parkinson’s disease candidate. 27 September 2024
Shionogi said today that it has submitted a New Drug Application (NDA) in Japan for zuranolone, a treatment in development for major depressive disorder (MDD). 27 September 2024
CNS specialist Lundbeck has announced data from the TALISMAN natural history study, as well as additional data from the AMULET trial, of amlenetug, in multiple system atrophy (MSA) at the International Congress of Parkinson's Disease and Movement disorders in Philadelphia, USA. 27 September 2024
Repair Biotechnologies, a company developing therapies to reverse atherosclerotic plaque, has entered into a collaboration with Genevant Sciences, a specialist in nucleic acid delivery technology. 27 September 2024
China’s National Medical Products Administration (NMPA) has approved Dupixent (dupilumab) as an add-on maintenance treatment for adults with uncontrolled chronic obstructive pulmonary disease (COPD). 27 September 2024
Chicago, USA-based ARCH Venture Partners revealed it has closed the ARCH Venture Fund XIII, a venture capital fund with more than $3 billion to support the founding and growth of early-stage biotechnology companies. 27 September 2024
US virology and immunology company Enanta Pharmaceuticals has given further weight to its claims to have the leading portfolio of potent respiratory syncytial virus (RSV) replication inhibitors 27 September 2024
Sage Therapeutics has announced that Biogen has terminated its partnership on the SAGE-324 program, following the recent failure of the drug in a Phase II study for the treatment of essential tremor. 27 September 2024
A US Food and Drug Administration advisory committee meeting has recommended restricting the use of PD-1 inhibitors, in a move which could affect blockbuster products such as Bristol Myers Squibb's Opdivo (nivolumab) and Merck & Co's Keytruda (pembrolizumab). 27 September 2024
The US Food and Drug Administration yesterday approved pharma major Bristol Myers Squibb’s Cobenfy (xanomeline and trospium chloride) capsules for oral use for the treatment of schizophrenia in adults. 27 September 2024
USA-based biotech funder and incubator Flagship Pioneering yesterday unveiled Mirai Bio, a company pioneering the first open end-to-end platform for the biotech industry to enable the co-creation of fully optimized genetic medicines. 27 September 2024
Antibody-drug conjugates (ADCs) represent a significant advancement in cancer treatment, particularly within China's burgeoning oncology sector. 27 September 2024
US drugmaker AbbVie has announced positive topline results from its pivotal Phase III TEMPO-1 trial for tavapadon as a monotherapy in early Parkinson's disease. 26 September 2024
Evaxion Biotech has entered into an option and license agreement with MSD (tradename of Merck & Co outside of the USA and Canada), for two pre-clinical vaccine candidates. 26 September 2024
Danish CNS specialist Lundbeck and US privately-held biotech Iambic Therapeutics today announced a strategic research collaboration to focus on discovery of a small molecule therapeutic for the treatment of migraine. 26 September 2024
The generics and biosimilars trade group, Medicines for Europe, has put out a strong message amid ongoing discussions on a European Union (EU) Critical Medicines Act. 26 September 2024
Pfizer (NYSE: PFE) has announced the withdrawal of Oxbryta (voxelotor), a treatment for sickle cell disease (SCD), from all global markets. 26 September 2024
Vifor Pharma was trading 5% lower at the end of trading on Wednesday while its partner Angion Biomedica lost more than 50% of its market value in the first half of the day’s trading in New York. 27 October 2021
UK drugmaker GlaxoSmithKline reported sales for the third quarter of £9.08 billion ($12.47), an increase of 5% on the same period in 2020 and ahead of the £8.7 billion predicted by analysts. 27 October 2021
Japan’s leading drugmaker Takeda Pharmaceutical today said it is exercising its option to acquire UK-based GammaDelta Therapeutics, an Abingworth portfolio company, focused on exploiting the unique properties of gamma delta (γδ) T cells for immunotherapy. 27 October 2021
Shares of Israel’s Teva Pharmaceutical Industries were down almost 5% at 2,975 shekels today, after it reported results for the quarter ended September 30, 2021, which was below the analysts' consensus on both revenue and profit. 27 October 2021
Privately-held German pharma major Boehringer Ingelheim and Austria’s Thoeris have announced a collaboration and license deal aimed at investigating new first-in-class therapies for patients with urea cycle disorders (UCDs). 27 October 2021
In October 2016, Gabriel Baertschi left his role as president and general manager of AstraZeneca in Japan to take the top job at Germany’s Grünenthal Group. 27 October 2021
Non-profit organization the Medicines Patent Pool (MPP) and MSD, the ex-North America name of Merck & Co, have signed a voluntary licensing agreement to facilitate affordable global access for molnupiravir, an investigational oral COVID-19 antiviral medicine developed by the US pharma giant. 27 October 2021
The US Food and Drug Administration’s Vaccines and Related Biological Products Advisory Committee (VRBPAC) has voted 17 to 0, with 1 abstention, to recommend that the FDA grant Emergency Use Authorization (EUA) for Comirnaty, the COVID-19 vaccine from Pfizer and BioNTech, in children five to 27 October 2021
Having risen nearly 50% over the last six month to $57.68, US biotech Cortexyme saw its shares tank 72% to $16.18 in after-hours trading yesterday, after it revealed that its investigational oral Alzheimer’s candidate failed to achieve a clinical goal. 27 October 2021
Israel’s Teva Pharmaceutical Industries and German drug developer MODAG GmbH have signed an exclusive worldwide licensing and development agreement for MODAG's lead compound anle138b and a related compound, sery433. 27 October 2021
Sanofi and Regeneron have shared results from a second Phase III trial assessing the investigational use of Dupixent (dupilumab) in patients 12 years and older with eosinophilic esophagitis (EoE). 26 October 2021
Now three years since its founding, US biotech Mammoth Biosciences, which is building the next generation of CRISPR products to cure and detect disease, has signed its first major R&D deal. 26 October 2021
US a multi-asset longevity biotech Cambrian Biopharma today announced the closing of an oversubscribed Series C financing, which raised $100 million. 26 October 2021
After years of questions about the future of its generics and biosimilars business Sandoz, Swiss pharma giant Novartis has finally announced a strategic review of the unit. 26 October 2021
US pharma major Eli Lilly today reported third-quarter 2021 financial results that did not live up to all analysts’ earnings hopes, despite better-than-expected top-line growth, sending the firm’s shares down 1.9% to $240.31 in early trading. 26 October 2021
UK-based biotech Bicycle Therapeutics today announced that Swiss pharma giant Roche’s subsidiary Genentech has exercised an option to initiate a new program, expanding the exclusive strategic collaboration agreement with Bicycle to discover, develop and commercialize novel Bicycle-based immuno-oncology therapies. 26 October 2021
US mRNA specialist Moderna has announced positive interim data from a Phase II/III study of the company’s vaccine against COVID-19, in children aged six to under 12 years of age. 26 October 2021
Paul Domenet, partner and communications creative director at Free The Birds, offers an Expert View on how big pharma can improve its image. 26 October 2021
US pharma giant Merck& Co yesterday announced positive top-line results from two pivotal Phase III trials of the investigational, once-daily oral fixed dose combination pill of doravirine/islatravir (DOR/ISL) in adults with HIV-1 infection who are virologically suppressed on different antiretroviral therapy regimens (ART; ILLUMINATE SWITCH A) or bictegravir/emtricitabine/tenofovir (BIC/FTC/TAF; ILLUMINATE SWITCH B). 26 October 2021
The news cycle has hit overdrive in the UK ahead of a frenetic couple of weeks that include the Autumn Budget, a Comprehensive Spending Review and the COP26 conference in Glasgow. 26 October 2021